These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Erring on the side of action: time for HIV programmes to implement isoniazid preventive therapy. Granich R; Getahun H; Reid A; Raviglione M; De Cock KM Int J Tuberc Lung Dis; 2009 Aug; 13(8):925-6. PubMed ID: 19723370 [No Abstract] [Full Text] [Related]
4. [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings]. Yoshiyama T Kekkaku; 2000 Nov; 75(11):629-41. PubMed ID: 11140086 [TBL] [Abstract][Full Text] [Related]
6. Tuberculosis preventive therapy for HIV-infected persons in less developed countries. Kritski AL Int J Tuberc Lung Dis; 2000 Feb; 4(2 Suppl 1):S76-81. PubMed ID: 10688154 [No Abstract] [Full Text] [Related]
7. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. Sterling TR; Brehm WT; Moore RD; Chaisson RE Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327 [TBL] [Abstract][Full Text] [Related]
8. Isoniazid prophylaxis in end-stage renal disease. Bal AM Transpl Infect Dis; 2006 Dec; 8(4):242-3; author reply 243. PubMed ID: 17116141 [No Abstract] [Full Text] [Related]
9. Isoniazid to prevent first and recurrent episodes of TB. Ayles H; Muyoyeta M Trop Doct; 2006 Apr; 36(2):83-6. PubMed ID: 16611439 [No Abstract] [Full Text] [Related]
10. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Fallab-Stubi CL; Zellweger JP; Sauty A; Uldry C; Iorillo D; Burnier M Int J Tuberc Lung Dis; 1998 Jul; 2(7):525-30. PubMed ID: 9661817 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Casado JL; Moreno S; FortĂșn J; Antela A; Quereda C; Navas E; Moreno A; Dronda F Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825 [TBL] [Abstract][Full Text] [Related]
15. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208 [TBL] [Abstract][Full Text] [Related]
16. Is INH alone enough for prophylaxis. Sanklecha MU; Raghavan K; Mehta MN Indian Pediatr; 1995 Jan; 32(1):105. PubMed ID: 8617518 [No Abstract] [Full Text] [Related]
17. Long-term outcome of isoniazid prophylaxis against tuberculosis in Chinese renal transplant recipients. Lui SL; Li FK; Choy BY; Chan TM; Lo WK; Lai KN Transpl Infect Dis; 2004 Mar; 6(1):55-6. PubMed ID: 15225230 [No Abstract] [Full Text] [Related]
18. A trial of mass isoniazid preventive therapy for tuberculosis control. Richardson ET; Wood R N Engl J Med; 2014 Apr; 370(17):1661-2. PubMed ID: 24758628 [No Abstract] [Full Text] [Related]
19. A trial of mass isoniazid preventive therapy for tuberculosis control. Ukwaja KN; Abimbola S N Engl J Med; 2014 Apr; 370(17):1661. PubMed ID: 24758627 [No Abstract] [Full Text] [Related]
20. Isoniazid TB prophylaxis effective in drug users with HIV. J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]